• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    Eupraxia Starts EP-104GI Phase 2b Trial in EoE Patients

    GLOBENEWSWIRE

    Eupraxia Pharma Announces Voting Results from Shareholder

    GLOBENEWSWIRE

    Eupraxia Pharmaceuticals to Present at Conferences in April

    GLOBENEWSWIRE

    Eupraxia’s DiffuSphere™ Shows 6+ Months Targeted Drug Release

    #N/A

    Eupraxia Pharma’s CEO to Join Webinar on Eosinophilic Esophagitis

    PR NEWSWIRE

    Renibus Shows RBT-1 Data At AMCP Nexus 2024 Meeting

    PR NEWSWIRE

    Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

    PR NEWSWIRE

    Eupraxia To Present At Controlled Release Society 2024 Annual Meeting

    PR NEWSWIRE

    Eupraxia CEO To Join Webinar On Osteoarthritis Rise On July 9, 2024

    PR NEWSWIRE

    Eupraxia Announces Voting Results From AGM And Special Meeting

    PR NEWSWIRE

    Eupraxia Eoe Trial Expansion: Resolve Phase 1b/2a Ep-104gi Announced

    PR NEWSWIRE

    Eupraxia Hosts KOL Event On EoE Program EP-104GI

    PR NEWSWIRE

    Eupraxia Announces Positive RESOLVE EoE Phase 1b/2a EP-104GI Data

    PR NEWSWIRE

    Eupraxia To Present EP-104GI Eosinophilic Esophagitis Data At DDW 2024

    PR NEWSWIRE

    Eupraxia Pharmaceuticals: Q1 2024 Financials, Corporate Update

    PR NEWSWIRE

    Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

    PR NEWSWIRE

    Eupraxia Presenting At Osteoarthritis Congress 2024

    PR NEWSWIRE

    Eupraxia To Present at Bloom Burton & Co. Healthcare Investor Conference

    PR NEWSWIRE

    Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today

    PR NEWSWIRE

    Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

    PR NEWSWIRE

    Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results

    PR NEWSWIRE

    Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering

    GLOBENEWSWIRE

    Eupraxia Announces Pricing of Overnight Marketed Offering of $30 Million

    GLOBENEWSWIRE

    Eupraxia Announces Overnight Marketed Offering of Approximately $30 Million

    GLOBENEWSWIRE

    Eupraxia Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial

    PR NEWSWIRE

    Eupraxia Pharmaceuticals Appoints CBO

    NEWSWIRE

    Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering

    GLOBENEWSWIRE

    Eupraxia Pharmaceuticals Announces Overnight Marketed Offering

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.